

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 December 2024 (26.12.2024)



(10) International Publication Number
WO 2024/263995 A9

(51) International Patent Classification:	63/622,675	19 January 2024 (19.01.2024)	US
	A61K 38/17 (2006.01) C07K 14/71 (2006.01)	25 January 2024 (25.01.2024)	US
	A61P 27/02 (2006.01)	12 February 2024 (12.02.2024)	US
(21) International Application Number:	63/556,308	21 February 2024 (21.02.2024)	US
	PCT/US2024/035127	15 March 2024 (15.03.2024)	US
(22) International Filing Date:	21 June 2024 (21.06.2024)		
(25) Filing Language:	English		
(26) Publication Language:	English		
(30) Priority Data:	63/523,019	23 June 2023 (23.06.2023)	US
	63/523,335	26 June 2023 (26.06.2023)	US
	63/531,758	09 August 2023 (09.08.2023)	US
	63/540,308	25 September 2023 (25.09.2023)	US
	63/546,476	30 October 2023 (30.10.2023)	US
	63/601,198	20 November 2023 (20.11.2023)	US
	63/604,484	30 November 2023 (30.11.2023)	US
	63/606,507	05 December 2023 (05.12.2023)	US
	63/606,887	06 December 2023 (06.12.2023)	US
	63/608,138	08 December 2023 (08.12.2023)	US
(71) Applicants:	REGENERON PHARMACEUTICALS, INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). BAYER HEALTHCARE LLC [US/US]; 100 Bayer Boulevard, Whippany, New Jersey 07981 (US).		
(72) Inventors:	VITTI, Robert L. ; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). BERLINER, Alyson J. ; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). CHU, Karen W. ; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). ASMUS, Friedrich ; Eitel-Fritz-Str. 2, 14129 Berlin (DE). DA SILVA LEAL, Sergio Casimiro ; In den Steinreben 6A, 4153 Reinach (CH). EISSING, Thomas ; Kirschbaum 15, 40764 Langen-		

(54) Title: EXTENDED, HIGH DOSE VEGF ANTAGONIST REGIMENS FOR TREATMENT OF ANGIOGENIC EYE DISORDERS




FIG. 73

(57) Abstract: The present invention relates to regimens for the treatment of angiogenic eye disorders such as nAMD, DR and DME characterized by high doses of aflibercept extended periods between doses.

[Continued on next page]

feld (DE). **RITTENHOUSE, Kay D.**; 15 Ridgewood Drive, Randolph, New Jersey 07869 (US).

(74) **Agent: TERMES, Lance A.**; Schwabe, Williamson & Wyatt PC, 1211 SW 5th Ave., Suite 1900, Portland, Oregon 97204 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(48) **Date of publication of this corrected version:**

27 February 2025 (27.02.2025)

(15) **Information about Correction:**

see Notice of 27 February 2025 (27.02.2025)